COMPOSITIONS AND METHODS FOR CANCER THERAPY

WIPO Patent Application WO/2020/132560

A3

One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound in any order together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Therapeutic Double Stranded RNA (tdsRNA) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately. Compositions for the practice of the method are also described.

WO/2023/046117	FGFR INHIBITORS AND METHODS OF USE THEREOF
WO/2014/015523	NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS
JP2013525304	Pyrrolopyrazinone kinase inhibitor

STRAYER DAVID (US)
EQUELS THOMAS (US)

PCT/US2019/068044

July 30, 2020

December 20, 2019

Click for automatic bibliography generation  

AIM IMMUNOTECH INC (US)

A61P35/00; A61K31/00; A61K39/00

WO2010047835A2

2010-04-29

CASEY AGER ET AL: "31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two", ILLIAJOURNAL FOR IMMUNOTHERAPY OF C, BIOMED CENTRAL LTD, LONDON, UK, vol. 4, no. 1, 16 November 2016 (2016-11-16), pages 107 - 221, XP021241441, DOI: 10.1186/S40425-016-0173-6
ANONYMOUS: "Hemispherx Announces New Data Showing Ampligen's Positive Role in Reprograming Tumor Microenvironment - Study Results Suggests Ampligen Could Materially Enhance the Effectiveness of Checkpoint Blockade Technology", 5 June 2018 (2018-06-05), pages 1 - 3, XP055675269, Retrieved from the Internet [retrieved on 20200310]
MARIE-NICOLE THEODORAKI ET AL: "Helicase-Driven Activation of NF[kappa]B-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment", CANCER RESEARCH, vol. 78, no. 15, 31 May 2018 (2018-05-31), US, pages 4292 - 4302,1-8, XP009519314, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-17-3985
ABDOU Y ET AL: "Chemokine modulation to enhance the effectiveness of pembrolizumab in patients with metastatic triple-negative breast cancer", CANCER IMMUNOLOGY RESEARCH 20190201 AMERICAN ASSOCIATION FOR CANCER RESEARCH INC. NLD, vol. 7, no. 2, 30 August 2018 (2018-08-30) - 3 October 2018 (2018-10-03), XP002798258, ISSN: 2326-6074
ANONYMOUS: "Table of Contents | Cancer Immunology Research", 1 February 2019 (2019-02-01), pages 1 - 5, XP055675352, Retrieved from the Internet [retrieved on 20200310]
ANONYMOUS: "Table of Contents - Trials in Progress | Cancer Immunology Research", 1 February 2019 (2019-02-01), pages 1 - 4, XP055675357, Retrieved from the Internet [retrieved on 20200310]
ANONYMOUS: "NCT03734692 - Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer", 6 December 2018 (2018-12-06), pages 1 - 8, XP055675368, Retrieved from the Internet [retrieved on 20200310]
ANONYMOUS: "Immuno-Oncology Summit", 1 January 2016 (2016-01-01), pages 1 - 27, XP055675510, Retrieved from the Internet [retrieved on 20200311]
CHRISTOPHER F. NICODEMUS ET AL: "Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy", AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY, vol. 202, no. 6, 1 June 2010 (2010-06-01), US, pages 608.e1 - 608.e8, XP055675519, ISSN: 0002-9378, DOI: 10.1016/j.ajog.2009.12.001
ANNIKA DE SOUSA LINHARES ET AL: "Not All Immune Checkpoints Are Created Equal", FRONTIERS IN IMMUNOLOGY, vol. 9, 31 August 2018 (2018-08-31), pages 1 - 15, XP055675799, DOI: 10.3389/fimmu.2018.01909
LAURA AGRESTA ET AL: "The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment", FRONTIERS IN IMMUNOLOGY, vol. 9, 28 November 2018 (2018-11-28), pages 1 - 9, XP055675805, DOI: 10.3389/fimmu.2018.02809

SINN, Eric (US)

View/Download PDF      PDF Help

Previous Patent: MELANIN BASED BIO-COMPOSITES FOR 3D PRINTING

Next Patent: TARGETED PROTEIN DEGRADATION